Skip to main content
. Author manuscript; available in PMC: 2019 Mar 7.
Published in final edited form as: Knee. 2018 Mar 7;25(2):296–305. doi: 10.1016/j.knee.2018.01.009

Table 6.

Influence of Time Frames and Covariates on IL-6 collected at the Six-Month Follow-Up Exam and Days Between Injury and Surgery

Covariate R2 (Unstandardized β) Between Covariate and IL-6 ΔR2 (Unstandardized β) Between Injury and Surgery and IL-6 after accounting for the covariate
Days Between Injury and Six-Month Follow-up 0.007 (0.001) 0.017 (−0.004)
Days Between ACLR and Six-Month Follow-up 0.022 (0.003) 0.002 (−0.001)
Body Mass Index 0.068 (−0.036) 0.005 (−0.002)
Sex 0.190 (0.308) 0.005 (−0.002)
Age 0.025 (−0.013) 0.001 (−0.001)
History of previous ACLR 0.079 (0.238) 0.008 (−0.002)
Concomitant Meniscal Injury 0.069 (−0.193) 0.008 (−0.002)
Concomitant Chondral Injury 0.018 (0.099) 0.001 (−0.001)
KOOS Symptoms at Initial Presentation 0.004 (−0.001) 0.007 (−0.002)
KOOS Pain at Initial Presentation 0.0002 (−0.0002) 0.007 (−0.002)
KOOS Daily Living at Initial Presentation 0.033 (0.003) 0.000002 (0.000003)
KOOS Sports at Initial Presentation 0.044 (0.003) 0.001 (−0.001)
KOOS Quality of Life at Initial Presentation 0.002 (0.001) 0.004 (−0.002)
Tegner Activity Scale at Six-Month Follow-Up 0.058 (−0.040) 0.000002 (0.000004)

ACLR – Anterior Cruciate Ligament Reconstruction, KOOS – Knee Osteoarthritis and Outcome Score, C2C – Type-II Collagen Cleavage Product, CPII – C-Propeptide of Type-II Collagen Procollagen, ARGS – Alanin-Arginine-Glycine-Serine, IL-6 – Interleukin-6, MMP-3 – Matrix Metalloproteinase-3

*

Significant F Change at p ≤ 0.05